Back to Search
Start Over
Arbidol is associated with increased in-hospital mortality among 109 patients with severe COVID-19: A multicenter, retrospective study
- Source :
- Journal of Global Health
- Publication Year :
- 2021
- Publisher :
- International Global Health Society, 2021.
-
Abstract
- Background The antiviral therapy has been considered as an ordinary intervention for COVID-19 patients. However, the effectiveness of antiviral therapy is uncertain. This study was designed to determine the association between the antiviral therapy and in-hospital mortality among severe COVID-19 patients. Methods This study enrolled severe COVID-19 patients admitted to four designated hospitals in Wuhan, China. The use of antiviral treatments, demographics, laboratory variables, co-morbidities, complications, and other treatments were compared between survival and fatal cases. The association between antiviral agents and in-hospital mortality were analyzed. Results In total, 109 severe COVID-19 patients (mean age 65.43) were enrolled for analysis, among which, 61 (56.0%) patients were discharged alive, and 48 (44.0%) died during hospitalization. We found no association between lopinavir/ritonavir (LPV/r) treatment and the in-hospital mortality (odds ratio (OR) = 0.195, 95% confidence interval (CI) = 0.023-1.679). Besides, ribavirin (OR = 0.738, 95% CI = 0.344-1.582), oseltamivir (OR = 0.765, 95% CI = 0.349-1.636), and interferon-alpha (IFN-α) (OR = 0.371, 95% CI = 0.112-1.236) were not associated with the in-hospital mortality. However, arbidol monotherapy (OR = 5.027, 95% CI = 1.795-14.074) or the combination of arbidol and oseltamivir (OR = 5.900, 95% CI = 1.190-29.247) was associated with an increased in-hospital mortality. In addition, the multiple logistic regression identified a significant association between the use of arbidol and the in-hospital mortality (adjusted OR = 4.195, 95% CI = 1.221-14.408). Conclusions Our findings indicated that LPV/r, IFN-α, ribavirin, or oseltamivir have no beneficial effects on the prognosis of severe COVID-19 patients, whereas the use of arbidol is associated with increased in-hospital mortality.
- Subjects :
- China
medicine.medical_specialty
Oseltamivir
Indoles
Severity of Illness Index
chemistry.chemical_compound
Internal medicine
Severity of illness
medicine
Humans
Hospital Mortality
Research Theme 1: COVID-19 Pandemic
Aged
Retrospective Studies
business.industry
Health Policy
Ribavirin
Public Health, Environmental and Occupational Health
COVID-19
Retrospective cohort study
Lopinavir
Odds ratio
Confidence interval
COVID-19 Drug Treatment
chemistry
Ritonavir
business
medicine.drug
Subjects
Details
- ISSN :
- 20472986 and 20472978
- Volume :
- 11
- Database :
- OpenAIRE
- Journal :
- Journal of Global Health
- Accession number :
- edsair.doi.dedup.....28c1af6f45a2ef35e96f2fb25923b7d3
- Full Text :
- https://doi.org/10.7189/jogh.11.05017